1. Sun Z, Fourcade J, Pagliano O, et al. Interleukin-10 and programmed
death-1 cooperate to regulate tumor antigen-specific CD8+ T cells in
melanoma patients. In: AACR; 2015.
2. Jana D, Sarkar DK, Ganguly S, et al. Role of cyclooxygenase 2 (COX-2)
in prognosis of breast cancer. Indian journal of surgical
oncology. 2014;5(1):59-65.
3. Wu C-T, Chang Y-H, Lin W-Y, Chen W-C, Chen M-F. TGF beta1 expression
correlates with survival and tumor aggressiveness of prostate cancer.Annals of surgical oncology. 2015;22(3):1587-1593.
4. Yang C, He L, He P, et al. Increased drug resistance in breast cancer
by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling
pathway. Medical oncology. 2015;32(2):14.
5. Masuda K, Hiraki A, Fujii N, et al. Loss or down-regulation of HLA
class I expression at the allelic level in freshly isolated leukemic
blasts. Cancer Science. 2007;98(1):102-108.
6. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors
inhibit T-cell activation by distinct mechanisms. Molecular and
cellular biology. 2005;25(21):9543-9553.
7. Walker LS. Treg and CTLA-4: two intertwining pathways to immune
tolerance. Journal of autoimmunity. 2013;45:49-57.
8. Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune
checkpoint molecules: signaling pathways and implications for cancer
immunotherapy. Clinical cancer research. 2013;19(18):4917-4924.
9. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and
co-inhibition. Nature Reviews Immunology. 2013;13(4):227-242.
10. Huse M. The T-cell-receptor signaling network. J Cell Sci.2009;122(9):1269-1273.
11. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4
combination blockade expands infiltrating T cells and reduces regulatory
T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci
U S A. 2010;107(9):4275-4280.
12. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or
Monotherapy in Untreated Melanoma. N Engl J Med.2015;373(13):1270-1271.
13. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab
versus ipilimumab in untreated melanoma. N Engl J Med.2015;372(21):2006-2017.
14. Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of
nivolumab in combination with ipilimumab in metastatic renal cell
carcinoma: the CheckMate 016 study. J Clin Oncol.2017;35(34):3851-3858.
15. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus
everolimus in advanced renal-cell carcinoma. New England Journal
of Medicine. 2015;373(19):1803-1813.
16. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with
metastatic DNA mismatch repair-deficient or microsatellite
instability-high colorectal cancer (CheckMate 142): an open-label,
multicentre, phase 2 study. The Lancet Oncology.2017;18(9):1182-1191.
17. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with
ipilimumab in patients with metastatic melanoma. N Engl J Med.2010;363(8):711-723.
18. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in
Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med.2015;373(2):123-135.
19. Prior LM, Harrold E, O’Leary CG, et al. Toxicities in immunotherapy:
Can they predict response? In: American Society of Clinical Oncology;
2016.
20. Varricchi G, Marone G, Mercurio V, Galdiero MR, Bonaduce D,
Tocchetti CG. Immune Checkpoint Inhibitors and Cardiac Toxicity: An
Emerging Issue. Curr Med Chem. 2018;25(11):1327-1339.
21. Ganatra S, Neilan TG. Immune Checkpoint Inhibitor-Associated
Myocarditis. Oncologist. 2018;23(8):879-886.
22. Atallah-Yunes SA, Kadado AJ, Kaufman GP, Hernandez-Montfort J.
Immune checkpoint inhibitor therapy and myocarditis: a systematic review
of reported cases. J Cancer Res Clin Oncol.2019;145(6):1527-1557.
23. Maughan BL, Bailey E, Gill DM, Agarwal N. Incidence of
immune-related adverse events with program death receptor-1-and program
death receptor-1 ligand-directed therapies in genitourinary cancers.Frontiers in oncology. 2017;7:56.
24. Palaskas N, Lopez‐Mattei J, Durand JB, Iliescu C, Deswal A. Immune
Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics,
Diagnosis, and Treatment. Journal of the American Heart
Association. 2020;9(2):e013757.
25. Graziano DF, Finn OJ. Tumor antigens and tumor antigen discovery.
In: Tumor Immunology and Cancer Vaccines. Springer; 2005:89-111.
26. Srivastava PK, Old LJ. Individually distinct transplantation
antigens of chemically induced mouse tumors. Immunology today.1988;9(3):78-83.
27. Smith-Garvin JE, Koretzky GA, Jordan MS. T Cell Activation.Annual Review of Immunology. 2009;27(1):591-619.
28. Belkaid Y. Regulatory T cells and infection: a dangerous necessity.Nature Reviews Immunology. 2007;7(11):875-888.
29. Veiga‐Parga T, Sehrawat S, Rouse BT. Role of regulatory T cells
during virus infection. Immunological reviews.2013;255(1):182-196.
30. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity.International journal of cancer. 2010;127(4):759-767.
31. Morse MA. Technology evaluation: ipilimumab, Medarex/Bristol-Myers
Squibb. Current opinion in molecular therapeutics.2005;7(6):588-597.
32. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated
inhibition in regulation of T cell responses: mechanisms and
manipulation in tumor immunotherapy. Annual review of immunology.2001;19(1):565-594.
33. Collins AV, Brodie DW, Gilbert RJ, et al. The interaction properties
of costimulatory molecules revisited. Immunity.2002;17(2):201-210.
34. Fallarino F, Fields PE, Gajewski TF. B7-1 engagement of cytotoxic T
lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.The Journal of experimental medicine. 1998;188(1):205-210.
35. Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB.
Structural analysis of CTLA-4 function in vivo. The Journal of
Immunology. 2000;164(10):5319-5327.
36. Francisco LM, Sage PT, Sharpe AH. The PD‐1 pathway in tolerance and
autoimmunity. Immunological reviews. 2010;236(1):219-242.
37. Yang H, Zhou X, Sun L, Mao Y. Correlation Between PD-L2 Expression
and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis.Frontiers in Oncology. 2019;9(47).
38. Bennett F, Luxenberg D, Ling V, et al. Program death-1 engagement
upon TCR activation has distinct effects on costimulation and
cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but
not CD28, IL-7, and IL-15 responses. The Journal of Immunology.2003;170(2):711-718.
39. Wherry EJ. T cell exhaustion. Nature immunology.2011;12(6):492-499.
40. Riley JL. PD‐1 signaling in primary T cells. Immunological
reviews. 2009;229(1):114-125.
41. Yao S, Wang S, Zhu Y, et al. PD-1 on dendritic cells impedes innate
immunity against bacterial infection. Blood, The Journal of the
American Society of Hematology. 2009;113(23):5811-5818.
42. Huang X, Venet F, Wang YL, et al. PD-1 expression by macrophages
plays a pathologic role in altering microbial clearance and the innate
inflammatory response to sepsis. Proceedings of the National
Academy of Sciences. 2009;106(15):6303-6308.
43. Carter LL, Fouser LA, Jussif J, et al. PD‐1: PD‐L inhibitory pathway
affects both CD4+ and CD8+ T cells and is overcome by IL‐2.European journal of immunology. 2002;32(3):634-643.
44. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1
Ligands, and Other Features of the Tumor Immune Microenvironment with
Response to Anti–PD-1 Therapy. Clinical Cancer Research.2014;20(19):5064-5074.
45. Loi S, Dushyanthen S, Beavis PA, et al. RAS/MAPK activation is
associated with reduced tumor-infiltrating lymphocytes in
triple-negative breast cancer: therapeutic cooperation between MEK and
PD-1/PD-L1 immune checkpoint inhibitors. Clinical Cancer
Research. 2016;22(6):1499-1509.
46. Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of
T‐cell inhibition and application to cancer therapy. Immunological
reviews. 2008;224(1):141-165.
47. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to
clinical application. International immunology.2007;19(7):813-824.
48. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of
long-term survival data from phase II and phase III trials of ipilimumab
in unresectable or metastatic melanoma. Journal of clinical
oncology. 2015;33(17):1889.
49. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of
response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature. 2014;515(7528):563-567.
50. Farolfi A, Ridolfi L, Guidoboni M, et al. Ipilimumab in advanced
melanoma: reports of long-lasting responses. Melanoma research.2012;22(3):263-270.
51. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of
non–small-cell lung cancer. New England Journal of Medicine.2015;372(21):2018-2028.
52. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and
long-term safety of nivolumab (anti–programmed death 1 antibody,
BMS-936558, ONO-4538) in patients with previously treated advanced
non–small-cell lung cancer. Journal of clinical oncology.2015;33(18):2004.
53. McDermott DF, Drake CG, Sznol M, et al. Survival, durable response,
and long-term safety in patients with previously treated advanced renal
cell carcinoma receiving nivolumab. Journal of clinical oncology.2015;33(18):2013.
54. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor
remission, and long-term safety in patients with advanced melanoma
receiving nivolumab. Journal of clinical oncology.2014;32(10):1020.
55. Fife BT, Bluestone JA. Control of peripheral T‐cell tolerance and
autoimmunity via the CTLA‐4 and PD‐1 pathways. Immunological
reviews. 2008;224(1):166-182.
56. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in
tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
57. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+
regulatory T cell function. Science. 2008;322(5899):271-275.
58. Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell
repertoire. Nature. 1999;402(6759):255-262.
59. Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune
checkpoint blockade. J Clin Invest. 2015;125(9):3377-3383.
60. Das R, Verma R, Sznol M, et al. Combination therapy with
anti–CTLA-4 and anti–PD-1 leads to distinct immunologic changes in
vivo. The Journal of Immunology. 2015;194(3):950-959.
61. Selby M, Engelhardt J, Lu L-S, et al. Antitumor activity of
concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in
preclinical models. In: American Society of Clinical Oncology; 2013.
62. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab
in advanced melanoma. N Engl J Med. 2013;369:122-133.
63. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe
AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal
multiorgan tissue destruction, revealing a critical negative regulatory
role of CTLA-4. Immunity. 1995;3(5):541-547.
64. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative
disorders with early lethality in mice deficient in Ctla-4.Science. 1995;270(5238):985-988.
65. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated
cardiomyopathy in PD-1 receptor-deficient mice. Science.2001;291(5502):319-322.
66. Ansari MJI, Salama AD, Chitnis T, et al. The programmed death-1
(PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD)
mice. The Journal of experimental medicine. 2003;198(1):63-69.
67. Kristiansen O, Larsen Z, Pociot F. CTLA-4 in autoimmune diseases–a
general susceptibility gene to autoimmunity? Genes & Immunity.2000;1(3):170-184.
68. Tocut M, Brenner R, Zandman-Goddard G. Autoimmune phenomena and
disease in cancer patients treated with immune checkpoint inhibitors.Autoimmunity reviews. 2018;17(6):610-616.
69. Menzies AM, Johnson D, Ramanujam S, et al. Anti-PD-1 therapy in
patients with advanced melanoma and preexisting autoimmune disorders or
major toxicity with ipilimumab. Annals of Oncology.2017;28(2):368-376.
70. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related
to clinical response in patients with metastatic melanoma treated by
CTL-associated antigen-4 blockade. Clinical Cancer Research.2007;13(22):6681-6688.
71. Weber JS, Kähler KC, Hauschild A. Management of immune-related
adverse events and kinetics of response with ipilimumab. Journal
of Clinical Oncology. 2012;30(21):2691-2697.
72. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in
patients with pretreated advanced melanoma: a randomised, double-blind,
multicentre, phase 2, dose-ranging study. The lancet oncology.2010;11(2):155-164.
73. Roth ME, Muluneh B, Jensen BC, Madamanchi C, Lee CB. Left
ventricular dysfunction after treatment with ipilimumab for metastatic
melanoma. American journal of therapeutics.2016;23(6):e1925-e1928.
74. Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with
Combination Immune Checkpoint Blockade. N Engl J Med.2016;375(18):1749-1755.
75. Ji C, Roy MD, Golas J, et al. Myocarditis in cynomolgus monkeys
following treatment with immune checkpoint inhibitors. Clinical
Cancer Research. 2019;25(15):4735-4748.
76. Balanescu DV, Donisan T, Palaskas N, et al. Immunomodulatory
treatment of immune checkpoint inhibitor-induced myocarditis: Pathway
toward precision-based therapy. Cardiovasc Pathol.2020;47:107211.
77. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of
immune-related adverse events in patients treated with immune checkpoint
inhibitor therapy: American Society of Clinical Oncology Clinical
Practice Guideline. Journal of clinical oncology: official journal
of the American Society of Clinical Oncology. 2018;36(17):1714.
78. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients
Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol.2018;71(16):1755-1764.
79. Escudier M, Cautela J, Malissen N, et al. Clinical Features,
Management, and Outcomes of Immune Checkpoint Inhibitor-Related
Cardiotoxicity. In: Circulation. Vol 136. United
States2017:2085-2087.
80. Rosenbaum E, Seier K, Kelly CM, et al. Association of immune-related
adverse events (irAEs) with improved clinical outcome in sarcoma
patients treated with immune checkpoint blockade (ICB). 2020 ASCO
Virtual Scientific Program; 2020.
81. Heidenreich PA, Kapoor JR. Radiation induced heart disease.Heart. 2009;95(3):252-258.
82. Nakamura K, Okuyama R. Immunotherapy for advanced melanoma: Current
knowledge and future directions. Journal of dermatological
science. 2016;83(2):87-94.
83. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS.
Intracellular trafficking of CTLA-4 and focal localization towards sites
of TCR engagement. Immunity. 1996;4(6):535-543.
84. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation
in the immunological synapse is regulated by TCR signal strength.Immunity. 2002;16(1):23-35.